DGX - Quest Diagnostics Incorporated Pick

Snowy mountain landscape with sunlit clouds and trees

Research brief

Jun 24, 2026 Afternoon

04:20 PM UTC

Quest Diagnostics Incorporated DGX medium

DGX

Conf. Medium

Pick Pr. $203.44

Stop Pr. $198.56

Trim Trimmed @ $215.39 | kept 30.2%

Curr. Pr. $231.84

Change +13.96%

Rem. Days 2

Executive Summary

Pick DGX as a Momentum trade, not a speculative balance-sheet turnaround, because Quest Diagnostics has a same-day primary-source catalyst: New York State Department of Health CLEP approved Haystack MRD, completing patient-testing authorization for the ctDNA MRD test across all 50 U.S. states after prior availability in 49 states and D.C. ir.questdiagnprnewswire.
The current stock_info recheck placed DGX at $203.29 at 2026-06-24 13:47 ET, above the $197.18 prior close, with beta 0.587, short float 3.11%, a 52-week high of $213.50, a mean analyst target of $223.44, and a high target of $245 finance.yahoo.
The 7-day thesis is that a fresh, objective healthcare access catalyst can help DGX outperform SPY over the same holding window, especially because final-gate stock_info showed SPY slightly red at $732.36 versus a $733.58 prior close and QQQ weaker at $708.79 versus a $713.65 prior close during the final recheck finance.yahoofinance.yahoofinance.yahoo.
The trade must be price disciplined: preferred entry is a $201-$203 hold or a reclaim/hold of $204.70 with improving volume, while a thin-volume chase above $204.70 is unattractive because the next completed-bar resistance is $207.50 before the $213.50 52-week high finance.yahoo.
Use a fail-fast stop at $198.50, which is near one ATR below the refreshed $203.29 price and near the prior-close/SMA20 cluster; that creates about 2.4% downside risk, while the $213.50 stretch target offers about 5.0% upside and roughly 2.1R against the fail-fast stop finance.yahoo.

Recent News

Quest announced on 2026-06-24 that NYSDOH CLEP approved Haystack MRD, a ctDNA liquid-biopsy minimal residual disease test for residual or recurring disease in solid tumors, and that approval makes the test authorized for patient testing in all 50 states ir.questdiagnprnewswire. This is the central 7-day catalyst because it is same-day, primary-source, regulatory-access related, and directly tied to a differentiated advanced-diagnostics product rather than a routine marketing update ir.questdiagnprnewswire.

Quest said Haystack MRD was developed under CLIA, had already been available for clinician ordering since late 2024 in 49 states and D.C., and can now be offered in New York after the CLEP approval ir.questdiagnprnewswire. The stock market implication is that the approval removes the last state-access gap for a product that was already commercialized elsewhere, which makes the catalyst more actionable than a pre-commercial research-only announcement ir.questdiagnprnewswire.

Quest cited a May 2025 New England Journal of Medicine study led by Memorial Sloan Kettering researchers in mismatch repair-deficient solid tumors, where Haystack MRD identified clinical complete response at a median 1.4 months versus more than 6 months for imaging ir.questdiagn. That evidence supports clinical relevance, but the 7-day trade should still treat the news as an access and positioning catalyst rather than proof of immediate revenue acceleration ir.questdiagn.

City of Hope is evaluating Haystack MRD across breast, colorectal, ovarian, and prostate cancer trials at fourteen U.S. sites, with research aimed at detecting minimal residual disease, monitoring treatment response, and identifying recurrence earlier than standard imaging newsroom.ques. This adds strategic credibility to the product arc, though it remains a medium-term clinical-adoption driver rather than a guaranteed near-term order-volume disclosure newsroom.ques.

Social confirmation is weak to neutral: the social scan found current news aggregation and company/clinical amplification around Haystack MRD, but it did not find a fresh retail discussion wave on Reddit, X, YouTube, or Threads that independently confirmed momentum stocktitan.nelinkedinstocktwitsreddit. That lowers squeeze potential, but it also lowers the risk that the setup is purely promotional retail heat stocktitan.nelinkedinstocktwitsreddit.

Company Overview

Quest Diagnostics is a large U.S. diagnostic-information-services company that serves one in three adult Americans, half of U.S. physicians and hospitals, and employs nearly 50,000 people ir.questdiag. Its core business model is broad laboratory testing and diagnostic information services, and the Haystack MRD product extends that platform into tumor-informed, next-generation ctDNA testing for minimal residual disease monitoring ir.questdiagnewsroom.ques.

Haystack MRD is designed to detect ultralow ctDNA levels and support monitoring for residual or recurrent cancer newsroom.ques. The product is strategically coherent with Quest's existing scale because national laboratory reach can matter when a test moves from state-by-state access to all-50-state availability ir.questdiagir.questdiagn.

The most relevant management signal in the current research set is operating guidance rather than a named executive change: management raised 2026 guidance to $11.78B-$11.90B of revenue and $10.63-$10.83 of adjusted diluted EPS, with expected full-year operating cash flow of about $1.75B and capex of about $550M ir.questdiag. That guidance supports the view that DGX is a solvent healthcare services compounder with a fresh product-access catalyst, not a distressed event trade ir.questdiagsec.gov.

Industry Analysis

DGX sits in healthcare services and diagnostics, which gave the finalist slate a useful diversification benefit versus higher-beta software, AI-services, and credit-platform candidates finance.yahoofinance.yahofinance.yahofinance.yaho. That matters for a one-week pick because the final-gate stock_info snapshot showed SPY and QQQ weaker at the recheck while DGX had an idiosyncratic healthcare catalyst finance.yahoofinance.yahoofinance.yahoo.

The laboratory-developed-test regulatory backdrop is not a near-term 7-day blocker in the saved research: FDA's 2024 LDT rule had been vacated by a federal district court on March 31, 2025, and FDA reverted the regulation to its pre-2024 text on September 19, 2025 fda.gov. That reduces immediate regulatory phase-in shock for the trade window, though Haystack commercialization still depends on physician adoption, payer coverage, clinical utility evidence, and competitive positioning versus other ctDNA MRD offerings ir.questdiagnnewsroom.ques.

The industry risk is that a state authorization milestone can expand access without immediately changing revenue, reimbursement, or ordering behavior ir.questdiagnnewsroom.ques. For that reason, the catalyst is good enough for a 7-day momentum trade, but it is not enough to justify ignoring price confirmation or buying a thin-volume chase above near resistance finance.yahoo.

Financial Analysis

DGX does not screen as a bankruptcy or going-concern risk candidate in the current research set sec.govfinance.yahoo. Q1 2026 net revenue was $2.895B, up 9.2% year over year, operating income was $399M, net income was $264M, diluted EPS was $2.24, and adjusted diluted EPS was $2.50 sec.govir.questdiag.

As of March 31, 2026, DGX had $2.566B of current assets, $2.177B of current liabilities, $16.673B of total assets, about $8.358B of total liabilities, $7.666B of equity, $393M of cash, and $5.658B of total debt sec.gov. Those 10-Q fields imply a current ratio of about 1.18 and working capital of about $389M, which is acceptable for the 7-day solvency gate even though it is not an excess-cash balance sheet sec.gov.

The deep-dive calculations produced book Altman Z'' near 3.74 and market-adjusted Z'' near 5.60, both above the 2.90 non-manufacturing distress threshold used in the screen sec.govfinance.yahoo. Using Yahoo/stock_info EBITDA of about $2.226B and 10-Q debt/cash, net debt/EBITDA was about 2.37x, while Q1 interest expense of $63M annualized implied EBITDA interest coverage of about 8.83x sec.govfinance.yahoo.

The current stock_info recheck showed DGX at $203.29, beta 0.587, short float 3.11%, 52-week high $213.50, mean analyst target $223.44, and high target $245 finance.yahoo. The analyst target framework indicates upside room, but it should be treated as a valuation and sentiment anchor rather than a guaranteed 7-day target finance.yahoo.

Investment Thesis

DGX is the best 7-day pick because the catalyst is fresh, objective, primary-source, and commercially relevant, while the balance sheet and liquidity checks pass ir.questdiagnprnewswiresec.govfinance.yahoo. The setup is Momentum because the trade depends on the market continuing to reprice a same-day access catalyst, not on a deep-value rerating or a speculative rescue ir.questdiagnfinance.yahoo.

The completed-session technical setup is constructive but not early: through 2026-06-23, DGX had SMA20 near $197.63, ATR14 near $4.75, completed-session RV20 near 1.15x, 5-day support near $192.83, and 20-day support near $191.02 finance.yahoo. At the $203.29 final-gate stock_info quote, DGX was about +1.19 ATR above SMA20 and same-day intraday volume was about 0.38x the 20-day average volume, so the stock is not dangerously overextended but still needs confirmation finance.yahoo.

The positive 7-day outcome case is that DGX holds the $200-$201 approval-gap area, reclaims or holds $204.70 with better volume, reaches the $207.50 first target, and then challenges the $213.50 52-week high if the all-50-state Haystack MRD catalyst attracts sustained institutional demand finance.yahooir.questdiagn. From the final-gate $203.29 quote, the $207.50 first target is about 2.1% upside and the $213.50 stretch target is about 5.0% upside, which can beat SPY over the same 7-day window if SPY remains choppy or only modestly positive finance.yahoofinance.yahoo.

The best rejected candidate, UPST, did not beat DGX because UPST had larger squeeze optionality but a less clean risk plan: it needed confirmation above $33.95-$34.00 for the first target to become attractive, carried 33.12% short float, had lending-cycle exposure, and had funding or balance-sheet complexity that makes it less suitable than DGX as the final 7-day pick ir.upstartir.upstartmarketbeatfinance.yaho. DGX has lower beta, lower short interest, no near earnings binary, and a primary-source healthcare access catalyst, which is a cleaner match for the 7-day objective finance.yahooir.questdiagir.questdiagn.

Risk Analysis

The main risk is catalyst fade: New York authorization is a real access milestone, but it is not the same as immediate reimbursement, order-volume disclosure, or FDA approval for a broad commercial indication ir.questdiagnnewsroom.ques. If DGX cannot hold the $200-$201 area after the approval pop, the market is likely treating the news as incremental rather than repricing-worthy finance.yahoo.

The overextension risk is moderate, not disqualifying: DGX was about +1.19 ATR above SMA20 at the $203.29 final-gate quote, below the $207.50 completed-bar resistance and below the $213.50 52-week high finance.yahoo. The setup should not be chased materially above $204.70 without improving volume because the first target at $207.50 is less than 1R versus the $198.50 fail-fast stop finance.yahoo.

The binary-event review is clean for the next seven calendar days: DGX has no scheduled earnings binary inside the next seven days, and the next listed earnings event is July 23, 2026 ir.questdiag. The main near-term event risk is therefore follow-through failure, not a scheduled earnings gap that could bypass the stop ir.questdiagfinance.yahoo.

Bankruptcy and going-concern risk are low for this trade because DGX has positive Q1 net income, positive operating income, raised 2026 guidance, acceptable current liquidity, book and market-adjusted Z'' scores above the non-manufacturing distress threshold, net debt/EBITDA near 2.37x, and EBITDA interest coverage near 8.83x sec.govir.questdiagfinance.yahoo. This does not make the trade risk-free, but it removes the distress-risk blocker that excluded or downgraded more speculative candidates finance.yahofinance.yahoo.

Social momentum is not a major positive input because the accessible scan found mostly official/company amplification and news aggregation rather than a fresh investor discussion burst stocktitan.nelinkedinstocktwitsreddit. That means price and volume confirmation matter more than sentiment confirmation for execution finance.yahoo.

Investment Recommendation

Recommend DGX as a Medium-confidence Momentum buy, but only with the specified entry discipline and fail-fast stop ir.questdiagnfinance.yahoo. Preferred entry is a $201-$203 hold or a $204.70 reclaim/hold with improving volume; acceptable current-price entry near the final-gate $203.29 stock_info quote requires the $200-$201 approval-gap area to remain intact finance.yahoo.

Use $198.50 as the official stop-loss, which is near one ATR below the refreshed $203.29 quote and near the completed-session prior-close/SMA20 cluster finance.yahoo. The structure logic is that a break below $198.50 would erase too much of the Haystack MRD approval reaction and put DGX back into the prior-close/SMA20 zone, while the volatility logic is that one ATR is enough room for normal noise in a 7-day catalyst trade without letting the position fall to the wider $192.83-$191.02 structural support band finance.yahoo.

The first target is $207.50, the stretch target is $213.50, and the $223.44 mean analyst target is an upside anchor rather than the base 7-day target finance.yahoo. If DGX loses $198.50 or fails to defend the $200-$201 approval-gap area after the catalyst, exit rather than waiting for the deeper $192.83-$191.02 support zone finance.yahoo.